Overview A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China Status: Recruiting Trial end date: 2023-10-01 Target enrollment: Participant gender: Summary This study will evaluate the efficacy and safety of CBP-201 in Chinese adult subjects with moderate to severe atopic dermatitis. Phase: Phase 2 Details Lead Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.